explore -WSS

explore

author：knowledge 2025-09-29 21:13:25 - browse：442

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Listen: Who gets the credit for GLP

WSS

In utero gene editing: an explainer

The Harvard botanist who searched for psychedelics in the Amazon

6 phony surgeries that take placebo to the extreme

Did you have Obamacare on your GOP debate bingo card?

Medicaid, Medicare dual

Data show record exodus of life scientists from academia

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Novavax promises a turnaround & Lilly roils the obesity market

Ionis has late

Dobbs anniversary: the lost opportunity of abortion as health care

Did you have Obamacare on your GOP debate bingo card?

After affirmative action ruling, medical educators look to 'holistic review'

Researchers use wearables data and AI to predict preterm birth risk

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Covid vaccines: Private market messier than government rollout

BioMarin wins approval for gene therapy to treat hemophilia A

Alabama hospital puts IVF treatments on hold

hotspot

FDA advisers vote against ALS treatment from BrainStorm

Antivenom research: Lessons from HIV applied in search for universal antidote

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Obesity drugs seen as possible treatment for liver disease MASH

Obesity drugs seen as possible treatment for liver disease MASH

knowledge

hotspot

hotspot

hotspot